Mode
Text Size
Log in / Sign up
Phase 2 N=26 Single-blind Treatment

The Role of Trans-spinal Direct Current Stimulation (tsDCS) in Treating Patients With Hand Spasticity After Stroke

Stroke · Cerebrovascular Accident (CVA) · Hemiparesis · Spasticity as Sequela of Stroke · Muscle Spasticity

Enrolled (actual)
26
Serious AEs
5.4%
Results posted
Sep 2019
Primary outcome: Primary: Mean Percent Change From Baseline in Area Under the Curve for Objectively Measured Spastic Catch Response of the Wrist Flexors at Fast Speed — 13.678; -8.783; 15.927; -16.333 percent change — p=0.004

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
sham Doublestim (Device); anodal Doublestim (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Northwell Health
Primary completion
Mar 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Mean Percent Change From Baseline in Area Under the Curve for Objectively Measured Spastic Catch Response of the Wrist Flexors at Fast Speed
13.678; -8.783; 15.927; -16.333 0.004 sig
SECONDARY
Mean Modified Tardieu Scale (MTS) Score
23.375; 21.625; 23.125; 21.975 0.003 sig

Summary

The purpose of this study is to evaluate if 5 consecutive sessions of PathMaker anodal DoubleStim treatment, which combines non-invasive stimulation of the spinal cord (tsDCS- trans-spinal direct current stimulation) and of the median nerve at the peripheral wrist (pDCS-- peripheral direct current stimulation), can significantly reduce spasticity of the wrist and hand after stroke.

Eligibility Criteria

Inclusion Criteria

  • First single focal unilateral hemisphere lesion with diagnosis verified by brain imaging (MRI or CT scans) that occurred at least 6 months prior
  • Cognitive function sufficient to understand the experiments and follow instructions
  • A Modified Ashworth Scale score between 1-3 points for wrist flexor and extensor muscles
  • A minimum of 15 degrees wrist passive range of motion (ROM) for wrist flexion and extension from wrist neutral position

Exclusion Criteria

  • Focal brainstem or thalamic infarcts
  • Prior surgical treatments for spasticity of the upper limb
  • Ongoing use of central nervous system (CNS)-active medications
  • Ongoing use of psychoactive medications, such as stimulants, antidepressants, and anti-psychotic medications
  • Botox or phenol alcohol treatment within 12 weeks of enrollment
  • Pregnancy in women, as determined by self-report
  • History of spinal cord injury or weakness
  • Chronic pain
  • Peripheral neuropathy including insulin dependent diabetes as determined by case history
  • Presence of additional potential tsDCS risk factors:
  • Damaged skin at the site of stimulation (i.e., skin with ingrown hairs, acne, razor nicks, wounds that have not healed recent scar tissue, broken skin, etc.)
  • Presence of an electrically, magnetically or mechanically activated implant (including cardiac pacemaker), an intracerebral vascular clip, or any other electrically sensitive support system
  • Highly conductive metal in any part of the body, including metal injury to the eye (jewelry must be removed during stimulation)
  • Past history of seizures or unexplained spells of loss of consciousness during the previous 36 months
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03080454). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search